Alkem Labs Q4 FY26 profit drops 27.7% to ₹236 crore on one-time loss; ₹10 dividend declared
Synopsis
Alkem Labs' headline profit fell 27.7% in Q4 FY26 — but the real story is underneath: strip out the ₹135 crore one-time charge and the business delivered 14.6% revenue growth and a 32.2% EBITDA jump, with margins expanding 200 basis points. The one-off distorts the picture; the operating trend points upward.
Key Takeaways
Alkem Laboratories reported a 27.7% fall in Q4 FY26 net profit to ₹236 crore , down from ₹306 crore in Q4 FY25.
The decline was driven by a one-time loss of ₹135 crore booked during the quarter.
Revenue from operations rose 14.6% year-on-year to ₹3,603 crore ; EBITDA jumped 32.2% to ₹517 crore .
EBITDA margin improved to 14.4% from 12.4% in the year-ago quarter.
A final dividend of ₹10 per share declared for FY26; record date set for 7 August , payment from 1 September .
Madhurima Singh appointed as Executive Director for five years from 20 December .
Alkem Laboratories Limited reported a 27.7 per cent year-on-year decline in consolidated net profit for the fourth quarter of fiscal 2026 (Q4 FY26), weighed down by a one-time loss recorded during the period. The Mumbai-headquartered pharmaceutical major posted a net profit of ₹236 crore for the quarter ended March 2026, against ₹306 crore in the same quarter of the previous year, according to its stock exchange filing.
One-Time Loss Dents the Bottom Line
Alkem Labs attributed the profit decline to a one-time loss of ₹135 crore booked in Q4 FY26. Stripping out this exceptional item, the underlying operational performance painted a considerably stronger picture, with both revenue and margins expanding meaningfully during the quarter.
Revenue and EBITDA Show Healthy Momentum
Consolidated revenue from operations grew 14.6 per cent year-on-year to ₹3,603 crore in the March quarter, up from ₹3,144 crore in Q4 FY25. EBITDA surged 32.2 per cent to ₹517 crore from ₹391 crore in the year-ago period. The EBITDA margin improved to 14.4 per cent from 12.4 per cent, reflecting better cost efficiencies and a stronger product mix. Notably, the double-digit revenue growth and margin expansion suggest the core business remained on a firm footing despite the one-time drag.
Dividend Declared for FY26
The company announced a final dividend of ₹10 per equity share for fiscal 2026, with a total estimated payout of nearly ₹119.57 crore. The record date has been fixed as 7 August to determine eligible shareholders. Payment is subject to shareholder approval at the upcoming annual general meeting and is slated to commence from 1 September onwards. Earlier in February 2026, Alkem Labs had declared an interim dividend of ₹43 per share. In prior years, the company paid dividends of ₹8 per share in August 2025, ₹37 per share in February 2025, and ₹5 per share in August 2024.
Board Appointment
Separately, the board announced the appointment of Madhurima Singh as Executive Director for a period of five years, effective 20 December. The appointment adds to the company's senior leadership as it navigates a period of operational expansion.
What to Watch
With the one-time loss now behind it, investor attention will shift to whether Alkem can sustain its double-digit revenue trajectory and defend margin gains through FY27. The company's domestic formulations business and its US generics pipeline remain the key variables to watch in the quarters ahead.
Point of View
Alkem delivered one of its stronger quarters in recent memory. The risk for investors is reading the net profit line in isolation. More pertinent is whether the margin expansion to 14.4% is structural or a one-quarter aberration driven by product mix. Indian pharma majors have repeatedly promised sustained margin improvement only to give it back when US pricing pressure returns. Alkem's FY27 guidance, when it comes, will be the real test of that thesis.
NationPress
12 Aug 2026
Frequently Asked Questions
Why did Alkem Labs' Q4 FY26 profit fall?
Alkem Labs' net profit fell 27.7% to ₹236 crore in Q4 FY26 primarily due to a one-time loss of ₹135 crore recorded during the quarter. Excluding this exceptional charge, the company's core operations showed strong growth in both revenue and EBITDA.
What was Alkem Labs' revenue in Q4 FY26?
Alkem Labs reported consolidated revenue from operations of ₹3,603 crore in Q4 FY26, a 14.6% increase year-on-year from ₹3,144 crore in Q4 FY25.
What dividend has Alkem Labs declared for FY26?
Alkem Labs declared a final dividend of ₹10 per equity share for fiscal 2026, with a total estimated payout of nearly ₹119.57 crore. The record date is 7 August, and payment is expected to begin from 1 September, subject to shareholder approval at the AGM.
How did Alkem Labs' EBITDA perform in Q4 FY26?
EBITDA rose 32.2% to ₹517 crore in Q4 FY26, up from ₹391 crore in the same quarter last year. EBITDA margin improved to 14.4% from 12.4%, indicating stronger operational efficiency.
Who has been appointed as Executive Director at Alkem Labs?
Madhurima Singh has been appointed as Executive Director of Alkem Laboratories for a period of five years, effective 20 December.
